4//SEC Filing
Norrett Kevin 4
Accession 0001209191-22-040236
CIK 0001290149other
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 4:28 PM ET
Size
13.7 KB
Accession
0001209191-22-040236
Insider Transaction Report
Form 4
Norrett Kevin
Chief Business Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2022-07-01−100,000→ 0 totalExercise: $12.05Exp: 2030-08-10→ Common Stock (100,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−49,000→ 0 totalExercise: $12.15Exp: 2030-08-12→ Common Stock (49,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−35,000→ 0 totalExercise: $31.54Exp: 2032-03-14→ Common Stock (35,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−11,700→ 0 totalExercise: $16.73Exp: 2031-03-15→ Common Stock (11,700 underlying)
Footnotes (5)
- [F1]The option vested as to 25% of the total shares on August 10, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
- [F3]On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
- [F4]The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
- [F5]The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.
Documents
Issuer
Sierra Oncology, Inc.
CIK 0001290149
Entity typeother
Related Parties
1- filerCIK 0001819690
Filing Metadata
- Form type
- 4
- Filed
- Jun 30, 8:00 PM ET
- Accepted
- Jul 1, 4:28 PM ET
- Size
- 13.7 KB